213 related articles for article (PubMed ID: 17063148)
1. Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis.
Spitzenberger TJ; Heilman D; Diekmann C; Batrakova EV; Kabanov AV; Gendelman HE; Elmquist WF; Persidsky Y
J Cereb Blood Flow Metab; 2007 May; 27(5):1033-42. PubMed ID: 17063148
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice.
Limoges J; Persidsky Y; Poluektova L; Rasmussen J; Ratanasuwan W; Zelivyanskaya M; McClernon DR; Lanier ER; Gendelman HE
Neurology; 2000 Jan; 54(2):379-89. PubMed ID: 10668699
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children.
Moolasart P; Likanonsakul S
Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):280-7. PubMed ID: 12236426
[TBL] [Abstract][Full Text] [Related]
4. Highly active antiretroviral therapy and human immunodeficiency virus encephalitis.
Cook JE; Dasgupta S; Middaugh LD; Terry EC; Gorry PR; Wesselingh SL; Tyor WR
Ann Neurol; 2005 Jun; 57(6):795-803. PubMed ID: 15852478
[TBL] [Abstract][Full Text] [Related]
5. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
Gartland M;
Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
[TBL] [Abstract][Full Text] [Related]
6. Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons.
Bartlett JA; Miralles GD; Sevin AD; Silberman M; Pruitt SK; Ottinger J; Gryszowska V; Fiscus SA; Bucy RP;
AIDS Res Hum Retroviruses; 2002 May; 18(8):535-43. PubMed ID: 12036483
[TBL] [Abstract][Full Text] [Related]
7. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
[TBL] [Abstract][Full Text] [Related]
8. ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages.
Jorajuria S; Dereuddre-Bosquet N; Becher F; Martin S; Porcheray F; Garrigues A; Mabondzo A; Benech H; Grassi J; Orlowski S; Dormont D; Clayette P
Antivir Ther; 2004 Aug; 9(4):519-28. PubMed ID: 15456083
[TBL] [Abstract][Full Text] [Related]
9. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
Matheron S; Descamps D; Boué F; Livrozet JM; Lafeuillade A; Aquilina C; Troisvallets D; Goetschel A; Brun-Vezinet F; Mamet JP; Thiaux C;
Antivir Ther; 2003 Apr; 8(2):163-71. PubMed ID: 12741629
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
11. Antiretrovirals for HIV nephropathy?
Saag M; Hecht F
AIDS Clin Care; 1999 Jun; 11(6):50. PubMed ID: 11366883
[TBL] [Abstract][Full Text] [Related]
12. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
[TBL] [Abstract][Full Text] [Related]
13. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
Plana M; Ferrer E; Martínez C; Podzamczer D; García F; Maleno MJ; Barceló JJ; García A; Barberá MJ; Lacarcel M; Miró JM; Gallart T; Gatell JM
Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
[TBL] [Abstract][Full Text] [Related]
14. Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.
Kakehasi FM; Tupinambás U; Cleto S; Aleixo A; Lin E; Melo VH; Aguiar RA; Pinto JA
AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1515-20. PubMed ID: 18160009
[TBL] [Abstract][Full Text] [Related]
15. Macrophage-induced inflammation affects hippocampal plasticity and neuronal development in a murine model of HIV-1 encephalitis.
Poluektova L; Meyer V; Walters L; Paez X; Gendelman HE
Glia; 2005 Dec; 52(4):344-53. PubMed ID: 16078235
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral rounds. When success is a pain.
Bartlett JG; del Rio C
AIDS Clin Care; 2001 Aug; 13(8):74-5. PubMed ID: 11547461
[No Abstract] [Full Text] [Related]
17. The efficacy of potent anti-retroviral drug combinations tested in a murine model of HIV-1 encephalitis.
Limoges J; Poluektova L; Ratanasuwan W; Rasmussen J; Zelivyanskaya M; McClernon DR; Lanier ER; Gendelman HE; Persidsky Y
Virology; 2001 Mar; 281(1):21-34. PubMed ID: 11222092
[TBL] [Abstract][Full Text] [Related]
18. Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis.
Poluektova LY; Munn DH; Persidsky Y; Gendelman HE
J Immunol; 2002 Apr; 168(8):3941-9. PubMed ID: 11937550
[TBL] [Abstract][Full Text] [Related]
19. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
20. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection.
Smith D; Berrey MM; Robertson M; Mehrotra D; Markowitz M; Perrin L; Clumeck N; Lazzarin A; Burckhardt B; Weber R; Corey L; Cooper DA
J Infect Dis; 2000 Sep; 182(3):950-4. PubMed ID: 10950796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
